Cepheid, of Sunnyvale, Calif., named Andrew D. Miller senior vice president and chief financial officer.

Ceragenix Pharmaceuticals Inc., of Denver, named Michael S. Niederman to its scientific advisory board.

Cerenis Therapeutics SA, of Toulouse, France, and Ann Arbor, Mich., appointed Robert A. Scott, chief medical officer.

Chelsea Therapeutics International Ltd., of Charlotte, N.C., named Roger Stoll and Norman Hardman to its board of directors. Jason Stein has resigned from the board.

Clinical Data Inc., of Newton, Mass., appointed William (Bill) Vernier vice president of operations for its PGxHealth division, which is a new position.

Cogentus Pharmaceuticals Inc., of Menlo Park, Calif., appointed a scientific steering committee to oversee a Phase III trial for CGT-2168, called COGENT, which includes: Deepak Bhatt, Marc Cohen, Byron Cryer, Angel Lanas and Thomas Schnitzer.

Crucell NV, of Leiden, the Netherlands, nominated Steve Davis to its supervisory board.

CryoCor Inc., of San Diego, appointed Warren Jackman to its scientific advisory board.

Cubist Pharmaceuticals Inc., of Lexington, Mass., named Steven Gilman senior vice president of discovery and nonclinical development and chief scientific officer.

Cylene Pharmaceuticals Inc., of San Diego, appointed Kenna Anderes vice president of cancer biology.

DiaKine Therapeutics Inc., of Charlottesville, Va., appointed Jonathan Lakey to its scientific advisory board.

enGene Inc., of Vancouver, British Columbia, appointed A. Sinclair Dunlop to its board of directors. John C. Brown and A. Lad Burgin are retiring from the board.

Galea Life Sciences Inc., of Miami, said its wholly owned subsidiary, BioSource Therapeutics Inc., named Edward Martin to its board.

Gentel Biosciences Inc., of Madison, Wis., named G. Randall Durnell vice president of commercial operations.

GenVault Corp., of Carlsbad, Calif., named Mark Ostrowski vice president of sales and marketing.

GeoVax Labs Inc., of Atlanta, appointed Harriet Robinson vice president of research and development.

Hana Biosciences Inc., of South San Francisco, named Christopher Salentine vice president of manufacturing and announced the departure of Fred Vitale as vice president and chief business officer.

Helicos Bioscience, of Cambridge, Mass., named Elisabeth Allison to its board of directors.

Histogen Inc., of San Diego, named Leonard Lavin to its board.

Indivumed, of Hamburg, Germany, named Harald R. Eistetter managing director and chief business officer.

InNexus Biotechnology Inc., of Vancouver, British Columbia, appointed Ronald Levy to its scientific advisory board.

KaloBios Pharmaceuticals Inc., of Palo Alto, Calif., named Carol Stratford general counsel and head of intellectual property and Charles Democko vice president of regulatory affairs and quality.

Keryx Biopharmaceuticals Inc., of New York, named Lou DeBergalis vice president of quality operations and appointed Eric Grossman vice president of medical affairs.

Koronis Pharmaceuticals, of Seattle, appointed Daniel H. Petree and George R. Painter to its board of directors.

Kythera Biopharmaceuticals Inc., of Los Angeles, named Joseph L. Turner to its board.

Laureate Pharma Inc., of Princeton, N.J., appointed Gary Swan vice president of operations.

Medgenics, of Vienna, Va., appointed Lord Steinberg to the company's board as a nonexecutive director.

MedImmune, of Gathersburg, Md., has named Peter A. Kiener executive vice president; Katy Strei vice president, people and organization development; Eileen Valenta vice president, operations and compliance, regulatory affairs; and Shou-Bai Chao vice president of vaccine manufacturing.